drug_type
RELEVANT_DRUG
intervention_type
Antibody–drug conjugate (HER2-directed)
drug_description
HER2-directed antibody–drug conjugate: trastuzumab linked via a cleavable linker to the topoisomerase I inhibitor deruxtecan. Binds HER2, is internalized, releases deruxtecan to induce DNA damage and apoptosis; also blocks HER2 signaling and mediates ADCC, with a bystander effect.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Trastuzumab Deruxtecan
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
HER2-targeted antibody–drug conjugate: trastuzumab binds HER2 and is internalized; a cleavable linker releases the membrane-permeable topoisomerase I inhibitor deruxtecan (DXd) in tumor cells, inducing DNA damage and apoptosis. The trastuzumab moiety also inhibits HER2 signaling and mediates ADCC, enabling a bystander cytotoxic effect.
drug_name
Trastuzumab deruxtecan (T-DXd)
nct_id_drug_ref
NCT06548178